Paul Waksman, PA
Medical · Falmouth, MANPI 1679034003
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,012 of the $2,779 with a category attached, or 72.4%. 34 manufacturers reported payments, led by Teleflex LLC at 33.1% of the total. Reporting peaked in 2023 at $1,534 and has fallen 56.9% since, to $660 in 2025. Among medical clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 78 payments — averaging $35.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teleflex LLC$921
- Urovant Sciences Inc$165
- Novo Nordisk$162
- Sumitomo Pharma America, Inc.$138
- 180 Medical, Inc.$136
- Medtronic$127
- plus $1K from 28 others
What the payments were for
- Travel & lodging$67824%
- Food & beverage$2,01272%
- Education$893%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teleflex LLC | 9 | $921 |
| Urovant Sciences Inc | 5 | $165 |
| Novo Nordisk | 4 | $162 |
| Sumitomo Pharma America, Inc. | 7 | $138 |
| 180 Medical, Inc. | 5 | $136 |
| Medtronic | 3 | $127 |
| Urogen Pharma, Inc. | 2 | $90 |
| Astellas Pharma US Inc | 1 | $89 |
| Zimmer Biomet | 2 | $76 |
| Accord Healthcare, Inc. | 3 | $73 |
| Bioventus LLC | 2 | $69 |
| Endo USA, Inc. | 2 | $68 |
| Ferring Pharmaceuticals Inc. | 3 | $67 |
| AbbVie | 3 | $62 |
| Telix Pharmaceuticals | 3 | $61 |
| Pacira Pharmaceuticals Incorporated | 2 | $55 |
| Tolmar, Inc. | 2 | $53 |
| Genentech USA, Inc. | 3 | $42 |
| Progenics Pharmaceuticals, Inc. | 2 | $36 |
| Johnson & Johnson | 1 | $35 |
| Halozyme Inc | 1 | $25 |
| Endo Pharmaceuticals Inc. | 1 | $24 |
| ABC Home Medical Supply, Inc. | 1 | $24 |
| BD | 1 | $22 |
| Dendreon Pharmaceuticals LLC | 1 | $22 |
| Antares Pharma, Inc. | 1 | $18 |
| Myovant Sciences Inc. | 1 | $18 |
| Immunitybio, Inc. | 1 | $16 |
| Coloplast | 1 | $16 |
| Axonics, Inc. | 1 | $15 |
| Merck | 1 | $14 |
| Acerus Pharmaceuticals Corporation | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Myriad Genetic Laboratories, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,779 in reported general payments places this provider in the 90th percentile of 421 medical providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 62 | $27,458 |
| MyrbetriqMirabegron | 13 | $14,396 |
| GemtesaVibegron | 11 | $9,637 |
| Tamsulosin Hcl | 92 | $1,939 |
| Methenamine Hippurate | 11 | $1,447 |
| Finasteride | 52 | $986 |
| Celecoxib | 81 | $429 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 19 | $297 |
| Oxycodone Hcl | 117 | $276 |
| Tramadol Hcl | 115 | $249 |
| Gabapentin | 110 | $234 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 26 | $113 |
| Dexamethasone | 30 | $97 |
| Amoxicillin | 61 | $69 |
| Ibuprofen | 12 | $60 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $35 | $27,45862 claims |
| Astellas Pharma US IncMyrbetriq | $89 | $14,39613 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $138 | $9,63711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 421 medical providers in Massachusetts.
Other medical in Falmouth
- Eileen CheeverLeominster$389K
- Vidal PrimiterioLawrence$22K
- Michelle BaytarianJamaica Plain$17K
- Julia FioreAgawam$16K
- Jennifer LevesqueFall River$15K
- Ashley HoffmanWestfield$13K
- Theresa FukudaBoston$13K
- Christina MessingerPlymouth$11K
- Lauren CarraSpringfield$9K
- Raul AliceaSpringfield$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.